5-硝基-1-(4-噻唑甲基)-1H-吲唑 | 833474-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 5-硝基-1-(4-噻唑甲基)-1H-吲唑
• 英文名称: 5-nitro-1-(1,3-thiazol-4-ylmethyl)-1H-indazole
• 英文别名: 5-Nitro-1-[(1,3-thiazol-4-yl)methyl]-1H-indazole；4-[(5-nitroindazol-1-yl)methyl]-1,3-thiazole
• CAS: 833474-36-5
• 化学式: C₁₁H₈N₄O₂S
• 分子量: 260.276
• InChiKey: KASJFEYCYQTEEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Bradbury Robert Hugh

  公开号：US20090048251A1

  公开（公告）日：2009-02-19

  A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.

  一种公式I的喹唑啉衍生物：其中取代基如文本中所定义，用于生产抗增殖效应，该效应在温血动物（如人）中单独或部分地通过抑制erbB2受体酪氨酸激酶而产生。
• 4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：AstraZeneca AB

  公开号：EP1928861A1

  公开（公告）日：2008-06-11
• 4- (IH-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：AstraZeneca AB

  公开号：EP1928861B1

  公开（公告）日：2010-11-17
• US7820683B2
  申请人：——

  公开号：US7820683B2

  公开（公告）日：2010-10-26
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005007083A2

  公开（公告）日：2005-01-27

  The present invention discloses thienopyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such thienopyrimidine derivatives are useful in the treatment of diseases associated with inappropriate ErbB family kinase activity.